GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Morgan, Kevin ^a   Meyer, Colette ^b   Miller, Nicola ^a   Sims, Andrew H ^b   Cagnan, Ilgin ^b   Faratian, Dana ^b   Harrison, David J ^b   Millar, Robert P ^a   Langdon, Simon P ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GONADORELIN RECEPTOR; INOSITOL PHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROGESTERONE RECEPTOR; SOMATOMEDIN C RECEPTOR; TRIPTORELIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ARTICLE; BREAST CANCER; BREAST CELL; CANCER GRADING; CELL GROWTH; CELL STRAIN HEK293; CELL SURFACE; CONTROLLED STUDY; GROWTH; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING; ANALYSIS OF VARIANCE; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECT; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; METABOLISM; METHODOLOGY; MICROARRAY ANALYSIS; PHYSIOLOGY; POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INOSITOL PHOSPHATES; MAP KINASE SIGNALING SYSTEM; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; RECEPTORS, LHRH; TRANSFECTION; TRIPTORELIN PAMOATE;

EID: 82355181536     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-476     Document Type: Article

References (46)

1. Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R. LHRH-agonists in Early Breast Cancer Overview group Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007, 369:1711-2173. LHRH-agonists in Early Breast Cancer Overview group.
2. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R, , Marth C. ABCSG-12 Trial Investigators Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New Engl J Med 2009, 360:679-691. 10.1056/NEJMoa0806285, 19213681, ABCSG-12 Trial Investigators.
3. Segal-Abramson T, Kitroser H, Levy J, Schally AV, Sharoni Y. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells. Proc Natl Acad Sci USA 1992, 89:2336-2339. 10.1073/pnas.89.6.2336, 48652, 1312718.
4. Hershkovitz E, Marbach M, Bosin E, Levy J, Roberts CT, LeRoith D, Schally AV, Sharoni Y. Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors. J Clin Endocrinol Metab 1993, 77:963-968. 10.1210/jc.77.4.963, 8408472.
5. Buchholz S, Seitz S, Schally AV, Engel JB, Rick FG, Szalontay L, Hohla F, Krishan A, Papadia A, Gaiser T, Brockhoff G, Ortmann O, Diedrich K, Köster F. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition. Int J Oncol 2009, 35:789-796.
6. Everest HM, Hislop JN, Harding T, Uney JB, Flynn A, Millar RP, McArdle CA. Signaling and antiproliferative effects mediated by GnRH receptors after expression in breast cancer cells using recombinant adenovirus. Endocrinology 2001, 142:4663-4672. 10.1210/en.142.11.4663, 11606431.
7. Schubert A, Hawighorst T, Emons G, Gründker C. Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo. Breast Cancer Res Treat 2011,
8. Morgan K, Stewart AJ, Miller N, Mullen P, Muir M, Dodds M, Medda F, Harrison D, Langdon S, Millar RP. Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo. Cancer Res 2008, 68:6331-6340. 10.1158/0008-5472.CAN-08-0197, 18676858.
9. Morgan K, Stavrou E, Leighton SP, Miller N, Sellar R, Millar RP. Elevated GnRH receptor expression plus GnRH agonist treatment inhibits the growth of a subset of papillomavirus 18-immortalized human prostate cells. Prostate 2010, 71:915-928.
10. Rose A, Froment P, Perrot V, Quon MJ, LeRoith D, Dupont J. The luteinizing hormone-releasing hormone inhibits the anti-apoptotic activity of insulin-like growth factor-1 in pituitary alphaT3 cells by protein kinase Calpha-mediated negative regulation of Akt. J Biol Chem 2004, 279:52500-52516. 10.1074/jbc.M404571200, 15448167.
11. Sims AH, Howell A, Howell SJ, Clarke RB. Origins of breast cancer subtypes and therapeutic implications. Nat Clin Pract Oncol 2007, 4:516-525. 10.1038/ncponc0908, 17728710.
12. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy?. Nat Rev Clin Oncol 2009, 6:718-730. 10.1038/nrclinonc.2009.166, 19942925.
13. Teschendorff AE, Caldas C. The breast cancer somatic 'muta-ome': tackling the complexity. Breast Cancer Res 2009, 11:301. 10.1186/bcr2236, 2688941, 19344493.
14. Dati C, Muraca R, Tazartes O, Antoniotti S, Perroteau I, Giai M, Cortese P, Sismondi P, Saglio G, De Bortoli M. c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. Int J Cancer 1991, 47:833-838. 10.1002/ijc.2910470607, 1672666.
15. Kurebayashi J. Biological and clinical significance of HER2 overexpression in breast cancer. Breast Cancer 2001, 8:45-51. 10.1007/BF02967477, 11180765.
16. Done SJ, Arneson NC, Ozçelik H, Redston M, Andrulis IL. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias. Cancer Res 1998, 58:785-789.
17. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008, 68:6084-6091. 10.1158/0008-5472.CAN-07-6854, 2680495, 18676830.
18. López-Knowles E, O'Toole SA, McNeil CM, Millar EK, Qiu MR, Crea P, Daly RJ, Musgrove EA, Sutherland RL. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010, 126:1121-1131.
19. Troxell ML, Levine J, Beadling C, Warrick A, Dunlap J, Presnell A, Patterson J, Shukla A, Olson NR, Heinrich MC, Corless CL. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. Mod Pathol 2010, 23:27-37. 10.1038/modpathol.2009.142, 19898424.
20. Yang J, Ren Y, Wang L, Li B, Chen Y, Zhao W, Xu W, Li T, Dai F. PTEN mutation spectrum in breast cancers and breast hyperplasia. J Cancer Res Clin Oncol 2010, 136:1303-1311. 10.1007/s00432-010-0781-3, 20300775.
21. Loi S, Sotiriou C, Haibe-Kains B, Lallemand F, Conus NM, Piccart MJ, Speed TP, McArthur GA. Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. BMC Med Genomics 2009, 2:37. 10.1186/1755-8794-2-37, 2706265, 19552798.
22. Cullen KJ, Allison A, Martire I, Ellis M, Singer C. Insulin-like growth factor expression in breast cancer epithelium and stroma. Breast Cancer Res Treat 1992, 22:21-29. 10.1007/BF01833330, 1421420.
23. Brünner N, Moser C, Clarke R, Cullen K. IGF-I and IGF-II expression in human breast cancer xenografts: relationship to hormone independence. Breast Cancer Res Treat 1992, 22:39-45. 10.1007/BF01833332, 1421423.
24. Zhang X, Yee D. Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res 2000, 2:170-175. 10.1186/bcr50, 138771, 11250706.
25. Maor S, Yosepovich A, Papa MZ, Yarden RI, Mayer D, Friedman E, Werner H. Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. Cancer Lett 2007, 257:236-243. 10.1016/j.canlet.2007.07.019, 17766039.
26. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE. Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008, 68:10238-10246. 10.1158/0008-5472.CAN-08-2755, 19074892.
27. Sabbatini P, Rowand JL, Groy A, Korenchuk S, Liu Q, Atkins C, Dumble M, Yang J, Anderson K, Wilson BJ, Emmitte KA, Rabindran SK, Kumar R. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin Cancer Res 2009, 15:3058-3067. 10.1158/1078-0432.CCR-08-2530, 19383820.
28. Chang SE. In vitro transformation of human epithelial cells. Biochimica et Biophysica Acta 1986, 823:161-194.
29. Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 2010, 21:1254-1261. 10.1093/annonc/mdp427, 19858088.
30. Katz E, Dubois-Marshall S, Sims AH, Faratian D, Li J, Smith ES, Quinn JA, Edward M, Meehan RR, Evans EE, Langdon SP, Harrison DJ. A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk. Br J Cancer 2010, 103:401-10. 10.1038/sj.bjc.6605763, 2920017, 20628393.
31. Cantalupo PG, Sáenz-Robles MT, Rathi AV, Beerman RW, Patterson WH, Whitehead RH, Pipas JM. Cell-type specific regulation of gene expression by simian virus 40 T antigens. Virology 2009, 386:183-191. 10.1016/j.virol.2008.12.038, 2737743, 19201438.
32. Wu A, Chen J, Baserga R. The role of insulin receptor substrate-1 in the oncogenicity of simian virus 40 T antigen. Cell Cycle 2008, 7:1999-2002. 10.4161/cc.7.13.6096, 18642444.
33. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res 2007, 5:195-201. 10.1158/1541-7786.MCR-06-0263, 17314276.
34. Ahmad T, Farnie G, Bundred NJ, Anderson NG. The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. J Biol Chem 2004, 279:1713-1719. 10.1074/jbc.M306156200, 14593113.
35. Surmacz E, Bartucci M. Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer. J Exp Clin Cancer Res 2004, 23:385-94.
36. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, Grohe C. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem 2000, 275:18447-18453. 10.1074/jbc.M910345199, 10749889.
37. Kozma SC, Bogaard ME, Buser K, Saurer SM, Bos JL, Groner B, Hynes NE. The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. Nucleic Acids Res 1987, 15:5963-5971. 10.1093/nar/15.15.5963, 306061, 3627975.
38. Bartucci M, Morelli C, Mauro L, Andò S, Surmacz E. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res 2001, 61:6747-6754.
39. Browaeys-Poly E, Perdereau D, Lescuyer A, Burnol AF, Cailliau K. Akt interaction with PLC(gamma) regulates the G(2)/M transition triggered by FGF receptors from MDA-MB-231 breast cancer cells. Anticancer Res 2009, 29:4965-4969.
40. Manavathi B, Acconcia F, Rayala SK, Kumar R. An inherent role of microtubule network in the action of nuclear receptor. Proc Natl Acad Sci USA 2006, 103:15981-15986. 10.1073/pnas.0607445103, 1635113, 17043237.
41. Callejas-Valera JL, Guinea-Viniegra J, Ramírez-Castillejo C, Recio JA, Galan-Moya E, Martinez N, Rojas JM, Ramón y Cajal S, Sánchez-Prieto R. E1a gene expression blocks the ERK1/2 signaling pathway by promoting nuclear localization and MKP up-regulation: implication in v-H-Ras-induced senescence. J Biol Chem 2008, 283:13450-13458. 10.1074/jbc.M709230200, 18316372.
42. Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marmé D, Rapp UR. Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 1993, 364:249-252. 10.1038/364249a0, 8321321.
43. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999, 286:1741-1744. 10.1126/science.286.5445.1741, 10576742.
44. Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M. Regulation of Raf-Akt Cross-talk. J Biol Chem 2002, 277:31099-31106. 10.1074/jbc.M111974200, 12048182.
45. Lobenhofer EK, Huper G, Iglehart JD, Marks JR. Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ 2000, 11:99-110.
46. Fukazawa H, Noguchi K, Murakami Y, Uehara Y. Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway. Mol Cancer Ther 2002, 1:303-309.